RARE Ultragenyx Pharmaceutical Inc.

-1.09  -2%
Previous Close 52.99
Open 52.92
Price To book 5.13
Market Cap 2203593970
Shares 42,458,458
Volume 227,214
Short Ratio 16.95
Av. Daily Volume 314,205

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released July 2016. Primary endpoint hit. Secondary missed. PDUFA date under priority review November 16, 2017.
Mucopolysaccharidosis 7 (MPS 7)
Phase 3 to be initiated 1H 2017.
UX007 (triheptanoin)
Glut1 DS patients with the movement disorder phenotype
Phase 3 data released August 22, 2017 - endpoints not met.
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
Phase 3 data released April 18, 2017 - primary endpoint met. BLA fiing announced August 24, 2017.
KRN23 Burosumab
X-Linked Hypophosphatemia (XLH) - adult
Interim data released April 2016. Additional data released September 2016.
KRN23 Burosumab
Tumor-induced osteomalacia (TIO)
Phase 2 initiated March 2014. Data released March 22, 2017 - primary endpoint not met. Phase 3 trial initiation announced April 27, 2017.
UX007 (triheptanoin)
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Phase 2 interim data released October 2015. 78-week data released November 30, 2016. Phase 3 planned.
UX007 (triheptanoin)
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

Latest News

  1. Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”
  2. Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx
  3. UPDATED: Dimension Therapeutics shares surge 38% on Ultragenyx bid
  4. Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers
  5. Ultragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in Cash
  6. Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical
  7. Ultragenyx's Burosumab Positive in Phase II for XLH and TIO
  8. Ultragenyx and Kyowa Hakko Kirin Announce Additional Burosumab Data in X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO) at ASBMR
  9. See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
  10. Ultragenyx to Present at the Morgan Stanley Global Healthcare Conference
  11. Ultragenyx to Present at the Baird 2017 Global Healthcare Conference
  12. Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate
  13. Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab’s Biologics License Application in the US
  14. Ultragenyx Announces Burosumab Data Presentations at ASBMR 2017 Annual Meeting
  15. Today's Research Reports on Stocks to Watch: Paratek Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc.
  16. Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today
  17. Why Omnicom Group Inc. (OMC), Ultragenyx Pharmaceutical Inc (RARE) and Stryker Corporation (SYK) Are 3 of Today’s Worst Stocks
  18. Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data